EE05073B1 - Retigabiin kasutamiseks neuropaatilise valu ravis - Google Patents

Retigabiin kasutamiseks neuropaatilise valu ravis

Info

Publication number
EE05073B1
EE05073B1 EEP200200145A EEP200200145A EE05073B1 EE 05073 B1 EE05073 B1 EE 05073B1 EE P200200145 A EEP200200145 A EE P200200145A EE P200200145 A EEP200200145 A EE P200200145A EE 05073 B1 EE05073 B1 EE 05073B1
Authority
EE
Estonia
Prior art keywords
retigabine
treatment
neuropathic pain
neuropathic
pain
Prior art date
Application number
EEP200200145A
Other languages
English (en)
Inventor
Rundfeldt Chris
Bartsch Reni
Rostock Angelika
Tober Christine
Dost Rita
Original Assignee
Viatris Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viatris Gmbh & Co. Kg filed Critical Viatris Gmbh & Co. Kg
Publication of EE200200145A publication Critical patent/EE200200145A/et
Publication of EE05073B1 publication Critical patent/EE05073B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
EEP200200145A 1999-09-27 2000-09-22 Retigabiin kasutamiseks neuropaatilise valu ravis EE05073B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/406,135 US6117900A (en) 1999-09-27 1999-09-27 Use of retigabine for the treatment of neuropathic pain
PCT/EP2000/009284 WO2001022953A2 (de) 1999-09-27 2000-09-22 Verwendung von retigabin zur behandlung von neuropathischen schmerzen

Publications (2)

Publication Number Publication Date
EE200200145A EE200200145A (et) 2003-04-15
EE05073B1 true EE05073B1 (et) 2008-10-15

Family

ID=23606675

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200145A EE05073B1 (et) 1999-09-27 2000-09-22 Retigabiin kasutamiseks neuropaatilise valu ravis

Country Status (35)

Country Link
US (1) US6117900A (et)
EP (1) EP1223927B1 (et)
JP (1) JP2003510273A (et)
KR (1) KR100730829B1 (et)
CN (2) CN101444498A (et)
AR (1) AR026163A1 (et)
AT (1) ATE288748T1 (et)
AU (1) AU777764B2 (et)
BG (1) BG65795B1 (et)
BR (1) BR0014293A (et)
CA (2) CA2384504C (et)
CZ (1) CZ295980B6 (et)
DE (1) DE50009504D1 (et)
DK (1) DK1223927T3 (et)
EE (1) EE05073B1 (et)
ES (1) ES2237461T3 (et)
HK (1) HK1052471A1 (et)
HR (1) HRP20020234A2 (et)
HU (1) HUP0202853A3 (et)
IL (3) IL148309A0 (et)
IS (1) IS6303A (et)
MX (1) MXPA02003179A (et)
NO (1) NO329744B1 (et)
NZ (1) NZ517616A (et)
PL (1) PL200847B1 (et)
PT (1) PT1223927E (et)
RS (1) RS50091B (et)
RU (1) RU2264813C2 (et)
SI (1) SI1223927T1 (et)
SK (1) SK286057B6 (et)
TR (1) TR200200706T2 (et)
TW (1) TWI257304B (et)
UA (1) UA72550C2 (et)
WO (1) WO2001022953A2 (et)
ZA (1) ZA200202449B (et)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6525062B2 (en) * 2000-06-09 2003-02-25 The Regents Of The University Of California Method of treating pain using nalbuphine and opioid antagonists
TWI287984B (en) 2000-10-17 2007-10-11 Wyeth Corp Pharmaceutical composition for modulating bladder function
US6589986B2 (en) * 2000-12-20 2003-07-08 Wyeth Methods of treating anxiety disorders
WO2002061075A1 (fr) * 2001-02-01 2002-08-08 Takeda Chemical Industries, Ltd. Proteine de recepteur couple aux proteines g et adn correspondant
JP2005507853A (ja) 2001-02-20 2005-03-24 ブリストル−マイヤーズ　スクイブ　カンパニー Ｋｃｎｑカリウムチャンネルモジュレーター並びに片頭痛および機構的に関連する疾患の治療におけるそれらの使用
AU2002338333A1 (en) * 2001-04-04 2002-10-21 Wyeth Methods for treating hyperactive gastric motility
EP1545535A4 (en) * 2002-09-05 2008-06-04 Scios Inc TREATMENT OF PAIN BY INHIBITION OF P38 MAP KINASE
US20080039461A1 (en) * 2002-09-05 2008-02-14 Protter Andrew A Treatment of pain by inhibition of p38 map kinase
US7632866B2 (en) * 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
AU2003296954A1 (en) * 2002-12-13 2004-07-09 The Regents Of The University Of California Analgesic combination comprising nalbuphine
BR0317748A (pt) * 2002-12-27 2005-11-22 Lundbeck & Co As H Composto, composição farmacêutica, e,uso de um composto
EP1578740B1 (en) * 2002-12-27 2007-03-21 H. Lundbeck A/S 1,2,4-triaminobenzene derivatives useful for treating disorders of the central nervous system
EP1631546A1 (en) * 2003-04-25 2006-03-08 H. Lundbeck A/S Sustituted indoline and indole derivatives
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
TWI349666B (en) 2004-03-12 2011-10-01 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivatives
PL2298766T3 (pl) 2005-03-03 2014-09-30 H Lundbeck As Preparaty farmaceutyczne zawierające podstawione pochodne pirydyny
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US20080045534A1 (en) * 2006-08-18 2008-02-21 Valeant Pharmaceuticals North America Derivatives of 1,3-diamino benzene as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
BRPI0716715B1 (pt) * 2006-08-23 2021-07-06 Xenon Pharmaceuticals, Inc Derivados de 4-(n-azacicloalquil) anilidas como moduladores de canal de potássio, seus usos, produto, composição, comprimido e cápsula
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
AU2007325629A1 (en) * 2006-11-28 2008-06-05 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
WO2009037707A2 (en) 2007-09-20 2009-03-26 Ramot At Tel Aviv University Ltd. N-phenyl anthranilic acid derivatives and uses thereof
EP2318001A4 (en) * 2008-07-18 2013-02-20 Valeant Pharmaceuticals Int FORMULATION WITH MODIFIED RELEASE AND USE METHOD
US20100323016A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
US20100323015A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
DE102009013611A1 (de) 2009-03-17 2010-09-23 Ratiopharm Gmbh Festes Retigabin in nicht-kristalliner Form
DE102009013613A1 (de) 2009-03-17 2010-09-23 Ratiopharm Gmbh Trockenverarbeitung von Retigabin
DE102009013612A1 (de) 2009-03-17 2010-09-23 Ratiopharm Gmbh Retigabin-Tabletten, bevorzugt mit modifizierter Freisetzung
IT1398282B1 (it) * 2009-07-30 2013-02-22 Difass S A Ora Farmapros S P A Composizione comprendente acido alfa-lipoico e carnosina per il trattamento della sindrome dell arto fantasma
US20110087650A1 (en) * 2009-10-06 2011-04-14 Johnson Controls Technology Company Creation and use of causal relationship models in building management systems and applications
TR201002473A2 (tr) * 2010-03-31 2011-09-21 Mustafa Nevzat �La� Sanay�� A.�. Herpes zoster hastalığının bır opiat reseptör antagonist kullanılarak tedavi yöntemi.
RU2446795C1 (ru) * 2011-03-31 2012-04-10 Федеральное государственное учреждение "Московский научно-исследовательский онкологический институт им. П.А. Герцена Министерства здравоохранения и социального развития Российской Федерации" ФГУ "МНИОИ им. П.А. Герцена "Минздравсоцразвития России" Способ предотвращения фантомного болевого синдрома после ампутации конечностей
CN102531966B (zh) * 2011-12-23 2013-07-24 山东创新药物研发有限公司 瑞替加滨的晶型d及其制备方法
US9320725B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
US9345689B2 (en) 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
CN103271899A (zh) * 2012-12-30 2013-09-04 北京阜康仁生物制药科技有限公司 瑞替加滨粉碎粒度在制剂中的应用
CN105919990A (zh) * 2016-06-29 2016-09-07 青岛云天生物技术有限公司 用于预防和治疗神经病理性疼痛的药物组合物及其用途
CN106176715A (zh) * 2016-06-29 2016-12-07 青岛云天生物技术有限公司 一种神经病理性疼痛治疗用药物组合物及其用途
US11369593B2 (en) 2017-07-14 2022-06-28 Texas Tech University System Functionalized pyridine carbamates with enhanced neuroprotective activity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4200259A1 (de) * 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
DE19539861A1 (de) * 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
GB9915414D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use

Also Published As

Publication number Publication date
RS50091B (sr) 2009-01-22
TR200200706T2 (tr) 2002-10-21
BG65795B1 (bg) 2009-12-31
HK1052471A1 (zh) 2003-09-19
KR100730829B1 (ko) 2007-06-20
CA2384504C (en) 2009-05-26
RU2264813C2 (ru) 2005-11-27
CN101444498A (zh) 2009-06-03
ATE288748T1 (de) 2005-02-15
MXPA02003179A (es) 2003-08-20
CZ295980B6 (cs) 2005-12-14
IL187030A (en) 2011-06-30
RU2002109240A (ru) 2004-01-10
IL148309A (en) 2007-12-03
ZA200202449B (en) 2003-03-26
IL148309A0 (en) 2002-09-12
CZ2002989A3 (cs) 2002-08-14
ES2237461T3 (es) 2005-08-01
PT1223927E (pt) 2005-06-30
WO2001022953A3 (de) 2002-05-23
SK286057B6 (sk) 2008-02-05
CN100522155C (zh) 2009-08-05
EP1223927A2 (de) 2002-07-24
BG106450A (en) 2002-09-30
JP2003510273A (ja) 2003-03-18
PL353393A1 (en) 2003-11-17
WO2001022953A2 (de) 2001-04-05
AR026163A1 (es) 2003-01-29
TWI257304B (en) 2006-07-01
SI1223927T1 (et) 2005-08-31
AU777764B2 (en) 2004-10-28
HUP0202853A2 (hu) 2002-12-28
CN1409632A (zh) 2003-04-09
DK1223927T3 (da) 2005-04-11
AU7906100A (en) 2001-04-30
EP1223927B1 (de) 2005-02-09
HUP0202853A3 (en) 2003-10-28
PL200847B1 (pl) 2009-02-27
UA72550C2 (en) 2005-03-15
NZ517616A (en) 2002-12-20
HRP20020234A2 (en) 2003-06-30
BR0014293A (pt) 2002-05-21
CA2384504A1 (en) 2001-04-05
SK2922002A3 (en) 2002-08-06
IL187030A0 (en) 2008-02-09
NO329744B1 (no) 2010-12-13
NO20021418L (no) 2002-03-21
EE200200145A (et) 2003-04-15
IS6303A (is) 2002-03-18
NO20021418D0 (no) 2002-03-21
CA2659048A1 (en) 2001-04-05
DE50009504D1 (de) 2005-03-17
KR20020042691A (ko) 2002-06-05
YU20302A (sh) 2005-03-15
US6117900A (en) 2000-09-12

Similar Documents

Publication Publication Date Title
EE05073B1 (et) Retigabiin kasutamiseks neuropaatilise valu ravis
DE60020327D1 (de) Wasserbehandlungsvorrichtung
EE200100480A (et) Ksenoon kasutamiseks närvimürgistuste ravis
EE05507B1 (et) Rosuvastatiini ZD4522) kasutamine heterosgootseperekondliku hperkolesteroleemia raviks
FI20000863A (fi) Uusi hoitomenetelmä
DE60040607D1 (de) Wasserbehandlungseinrichtung
HK1061212A1 (en) Pyranoindazoles and their use for the treatment ofglaucoma
EE200200571A (et) Hüdroksüfenüülpiperidiin-4-ülideenmetüülbensamiidi derivaadid valu raviks
NO20021964L (no) Biologisk fluidbehandling
DE60223576D1 (de) Hautbehandlungszusammensetzung
HUP0303236A3 (en) Carbamate compounds for use in the treatment of pain
GB0108671D0 (en) Skin treatment
GB0213869D0 (en) The treatment of pain
EE200200577A (et) Kinolinüülpiperidiin-4-ülideenmetüülbensamiidi derivaadid valu raviks
EE200200511A (et) Hüdroksüfenüülpiperasinüülmetüülbensamiidi derivaadid valu raviks
ITMI20001555A0 (it) Procedimento e dispositivo di trattamento elettrochimico
NO20013596D0 (no) Slambehandling
DE60022086D1 (de) Wasserbehandlung
ID30458A (id) Osanetan dalam pengobatan gangguan jiwa
IL164951A0 (en) The treatment of pain with lfendropil
EE200200348A (et) Ravimkoostis kasutamiseks valu ravis
DE29905089U1 (de) Behandlungsliege
GB0007217D0 (en) Materials and methods relating to the treatment of leukaemias
ID28817A (id) Penggunaan turunan-turunan tetrahidropiridin (atau4-hidropiperidin)-butilazol dalam pembuatan obat untuk perawatan nyeri
GB0325957D0 (en) The treatment of pain

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner
HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20081231

MM4A Lapsed by not paying the annual fees

Effective date: 20090922